Search Results - "Degraff, David J"

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants by Warrick, Joshua I., Sjödahl, Gottfrid, Kaag, Matthew, Raman, Jay D., Merrill, Suzanne, Shuman, Lauren, Chen, Guoli, Walter, Vonn, DeGraff, David J.

“…Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this…”
Get full text

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes by Meeks, Joshua J., Al-Ahmadie, Hikmat, Faltas, Bishoy M., Taylor, John A., Flaig, Thomas W., DeGraff, David J., Christensen, Emil, Woolbright, Benjamin L., McConkey, David J., Dyrskjøt, Lars

“…Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and intertumoural heterogeneity at the genomic, transcriptional and…”
Get full text

Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis by Xia, Yong, Liu, Yan, Yang, Chao, Simeone, Diane M., Sun, Tung-Tien, DeGraff, David J., Tang, Moon-shong, Zhang, Yingkai, Wu, Xue-Ru

“…Human chromosome 9p21.3 is susceptible to inactivation in cell immortalization and diseases, such as cancer, coronary artery disease and type-2 diabetes…”
Get full text

Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer by Iyyanki, Tejaswi, Zhang, Baozhen, Wang, Qixuan, Hou, Ye, Jin, Qiushi, Xu, Jie, Yang, Hongbo, Liu, Tingting, Wang, Xiaotao, Song, Fan, Luan, Yu, Yamashita, Hironobu, Chien, Ruby, Lyu, Huijue, Zhang, Lijun, Wang, Lu, Warrick, Joshua, Raman, Jay D, Meeks, Joshua J, DeGraff, David J, Yue, Feng

“…Muscle-invasive bladder cancers are characterized by their distinct expression of luminal and basal genes, which could be used to predict key clinical features…”
Get full text

Mouse models of prostate cancer: picking the best model for the question by Grabowska, Magdalena M., DeGraff, David J., Yu, Xiuping, Jin, Ren Jie, Chen, Zhenbang, Borowsky, Alexander D., Matusik, Robert J.

“…When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no…”
Get full text

Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone by Jin, Renjie, Sterling, Julie A, Edwards, James R, DeGraff, David J, Lee, Changki, Park, Serk In, Matusik, Robert J

“…Patients with advanced prostate cancer almost invariably develop osseous metastasis. Although many studies indicate that the activation of NF-κB signaling…”
Get full text

A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma by Warrick, Joshua I., Knowles, Margaret A., Hurst, Carolyn D., Shuman, Lauren, Raman, Jay D., Walter, Vonn, Putt, Jeffrey, Dyrskjøt, Lars, Groeneveld, Clarice, Castro, Mauro A. A., Robertson, A. Gordon, DeGraff, David J.

“…Human cancers display a restricted set of expression profiles, despite diverse mutational drivers. This has led to the hypothesis that select sets of…”
Get full text

Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer by Osei-Amponsa, Vasty, Buckwalter, Jenna M., Shuman, Lauren, Zheng, Zongyu, Yamashita, Hironobu, Walter, Vonn, Wildermuth, Thomas, Ellis-Mohl, Justine, Liu, Chang, Warrick, Joshua I., Shantz, Lisa M., Feehan, Robert P., Al-Ahmadie, Hikmat, Mendelsohn, Cathy, Raman, Jay D., Kaestner, Klaus H., Wu, Xue-Ru, DeGraff, David J.

“…Intratumoral heterogeneity in bladder cancer is a barrier to accurate molecular sub-classification and treatment efficacy. However, individual cellular and…”
Get full text

Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming by Buj, Raquel, Chen, Chi-Wei, Dahl, Erika S., Leon, Kelly E., Kuskovsky, Rostislav, Maglakelidze, Natella, Navaratnarajah, Maithili, Zhang, Gao, Doan, Mary T., Jiang, Helen, Zaleski, Michael, Kutzler, Lydia, Lacko, Holly, Lu, Yiling, Mills, Gordon B., Gowda, Raghavendra, Robertson, Gavin P., Warrick, Joshua I., Herlyn, Meenhard, Imamura, Yuka, Kimball, Scot R., DeGraff, David J., Snyder, Nathaniel W., Aird, Katherine M.

“…Reprogrammed metabolism and cell cycle dysregulation are two cancer hallmarks. p16 is a cell cycle inhibitor and tumor suppressor that is upregulated during…”
Get full text

Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis by Choudhary, Shilpa, Hegde, Poornima, Pruitt, James R, Sielecki, Thais M, Choudhary, Dharamainder, Scarpato, Kristen, Degraff, David J, Pilbeam, Carol C, Taylor, 3rd, John A

“…Macrophage migratory inhibitory factor (MIF) is a proinflammatory cytokine shown to promote tumorigenesis. Using the N-butyl-N-(4-hydroxybutyl)-nitrosamine…”
Get full text

Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer by Reddy, Opal L, Cates, Justin M, Gellert, Lan L, Crist, Henry S, Yang, Zhaohai, Yamashita, Hironobu, Taylor, John A, Smith, Joseph A, Chang, Sam S, Cookson, Michael S, You, Chaochen, Barocas, Daniel A, Grabowska, Magdalena M, Ye, Fei, Wu, Xue-Ru, Yi, Yajun, Matusik, Robert J, Kaestner, Klaus H, Clark, Peter E, DeGraff, David J

“…We previously found loss of forkhead box A1 (FOXA1) expression to be associated with aggressive urothelial carcinoma of the bladder, as well as increased tumor…”
Get full text

Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems by Buckwalter, Jenna M, Chan, Wilson, Shuman, Lauren, Wildermuth, Thomas, Ellis-Mohl, Justine, Walter, Vonn, Warrick, Joshua I, Wu, Xue-Ru, Kaag, Matt, Raman, Jay D, DeGraff, David J

“…Epigenetic aberrations are prominent in bladder cancer (BC) and contribute to disease pathogenesis. We characterized histone deacetylase (HDAC) expression, a…”
Get full text

TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p by Patel, Girijesh, Dutta, Sayanika, Mahmud Syed, Mosharaf, Ramachandran, Sabarish, Sharma, Monica, Rajamanickam, Venkatesh, Ganapathy, Vadivel, DeGraff, David, Pruitt, Kevin, Tripathi, Manisha, Nandana, Srinivas

“…Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies…”
Get full text

Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation by DeGraff, David J, Clark, Peter E, Cates, Justin M, Yamashita, Hironobu, Robinson, Victoria L, Yu, Xiuping, Smolkin, Mark E, Chang, Sam S, Cookson, Michael S, Herrick, Mary K, Shariat, Shahrokh F, Steinberg, Gary D, Frierson, Henry F, Wu, Xue-Ru, Theodorescu, Dan, Matusik, Robert J

“…Approximately 50% of patients with muscle-invasive bladder cancer (MIBC) develop metastatic disease, which is almost invariably lethal. However, our…”
Get full text

Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder by Adam, Rosalyn M., Ph.D, DeGraff, David J., Ph.D

“…Abstract Background Recent molecular characterization studies focusing on bladder cancer have provided a wealth of information, including the identification of…”
Get full text

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023 by Joshi, Monika, Tuanquin, Leonard, Zhu, Junjia, Walter, Vonn, Schell, Todd, Kaag, Matthew, Kilari, Deepak, Liao, Jiangang, Holder, Sheldon L, Emamekhoo, Hamid, Sankin, Alexander, Merrill, Suzzane, Zheng, Hong, Warrick, Joshua, Hauke, Ralph, Gartrel, Benjamin, Stein, Mark, Drabick, Joseph, Degraff, David J, Zakharia, Yousef

“…BackgroundPatients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed…”
Get full text

FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype by DeGraff, David J, Grabowska, Magdalena M, Case, Tom C, Yu, Xiuping, Herrick, Mary K, Hayward, William J, Strand, Douglas W, Cates, Justin M, Hayward, Simon W, Gao, Nan, Walter, Michael A, Buttyan, Ralph, Yi, Yajun, Kaestner, Klaus H, Matusik, Robert J

“…The forkhead box (Fox) superfamily of transcription factors has essential roles in organogenesis and tissue differentiation. Foxa1 and Foxa2 are expressed…”
Get full text

Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation by Torab, Peter, Yan, Yue, Ahmed, Mona, Yamashita, Hironobu, Warrick, Joshua I, Raman, Jay D, DeGraff, David J, Wong, Pak Kin

“…Cellular and molecular heterogeneity within tumors has long been associated with the progression of cancer to an aggressive phenotype and a poor prognosis…”
Get full text

Clinical Significance of Prominent Retraction Clefts in Invasive Urothelial Carcinoma by Shah, Tanmay S., DO, Kaag, Matthew, MD, Raman, Jay D., MD, Chan, Wilson, Tran, Truc, Kunchala, Sudhir, Shuman, Lauren, DeGraff, David J., PhD, Chen, Guoli, MD, PhD, Warrick, Joshua I., MD

“…Micropapillary morphology in invasive urothelial carcinoma is an established predictor of aggressive disease. It is unknown, however, if prominent retraction…”
Get full text

Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer by Warrick, Joshua I., M.D, Raman, Jay D., M.D, Kaag, Matthew, M.D, Bruggeman, Trey, B.S, Cates, Justin, M.D, Clark, Peter, M.D, DeGraff, David J., Ph.D

“…Abstract Background Studies evaluating enhancer of zeste homolog 2 (EZH2) expression and oncologic outcomes in bladder cancer have been discrepant. EZH2…”
Get full text